WallStreetZenWallStreetZen

NASDAQ: BDRX
Biodexa Pharmaceuticals PLC Stock

$1.53-0.09 (-5.56%)
Updated Feb 21, 2024
BDRX Price
$1.53
Fair Value Price
N/A
Market Cap
$1.28M
52 Week Low
$1.21
52 Week High
$182.34
P/E
-0.08x
P/B
0.2x
P/S
0.53x
PEG
N/A
Dividend Yield
N/A
Revenue
$359.04k
Earnings
-$4.52M
Gross Margin
100%
Operating Margin
-1,286.58%
Profit Margin
-1,197.3%
Debt to Equity
0.5
Operating Cash Flow
-$11M
Beta
0.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

BDRX Overview

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BDRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BDRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BDRX is good value based on its book value relative to its share price (0.2x), compared to the US Biotechnology industry average (5.97x)
P/B vs Industry Valuation
BDRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BDRX due diligence checks available for Premium users.

Be the first to know about important BDRX news, forecast changes, insider trades & much more!

BDRX News

Valuation

BDRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.08x
Industry
16.04x
Market
28.8x

BDRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.2x
Industry
5.97x
BDRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

BDRX's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BDRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$10.1M
Liabilities
$3.4M
Debt to equity
0.5
BDRX's short-term assets ($8.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDRX's short-term assets ($8.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BDRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

BDRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BDRX$1.28M-5.56%-0.08x0.20x
TENX$1.30M+9.02%-0.05x0.11x
SPRC$1.18M+3.73%0.79x1.15x
DRMA$1.37M-2.71%-0.08x0.21x
PXMD$1.40M-4.39%-0.02x-2.60x

Biodexa Pharmaceuticals Stock FAQ

What is Biodexa Pharmaceuticals's quote symbol?

(NASDAQ: BDRX) Biodexa Pharmaceuticals trades on the NASDAQ under the ticker symbol BDRX. Biodexa Pharmaceuticals stock quotes can also be displayed as NASDAQ: BDRX.

If you're new to stock investing, here's how to buy Biodexa Pharmaceuticals stock.

What is the 52 week high and low for Biodexa Pharmaceuticals (NASDAQ: BDRX)?

(NASDAQ: BDRX) Biodexa Pharmaceuticals's 52-week high was $182.34, and its 52-week low was $1.21. It is currently -99.16% from its 52-week high and 26.45% from its 52-week low.

How much is Biodexa Pharmaceuticals stock worth today?

(NASDAQ: BDRX) Biodexa Pharmaceuticals currently has 277,971,722 outstanding shares. With Biodexa Pharmaceuticals stock trading at $1.53 per share, the total value of Biodexa Pharmaceuticals stock (market capitalization) is $1.28M.

Biodexa Pharmaceuticals stock was originally listed at a price of $588,000.00 in Dec 7, 2015. If you had invested in Biodexa Pharmaceuticals stock at $588,000.00, your return over the last 8 years would have been -100%, for an annualized return of -79.96% (not including any dividends or dividend reinvestments).

How much is Biodexa Pharmaceuticals's stock price per share?

(NASDAQ: BDRX) Biodexa Pharmaceuticals stock price per share is $1.53 today (as of Feb 21, 2024).

What is Biodexa Pharmaceuticals's Market Cap?

(NASDAQ: BDRX) Biodexa Pharmaceuticals's market cap is $1.28M, as of Feb 22, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Biodexa Pharmaceuticals's market cap is calculated by multiplying BDRX's current stock price of $1.53 by BDRX's total outstanding shares of 277,971,722.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.